StillsNow Podcast December 2023 – ACR23 Highlights
Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023…
View Resource
Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
Editor’s note: this article originally appeared July 26, 2023, and is being shared again…
View Resource
Best of 2023: LAVLI – A New Autoinflammatory Disorder
Editor’s note: this article originally appeared March 28, 2023, and is being shared again…
View Resource
ICYMI: Here at Last: Treatment Options for VEXAS
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…
View Resource
CBT or Naltrexone in Fibromyalgia (12.8.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on…
View Resource
ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease
Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to…
View Resource
Here at Last: Treatment Options for VEXAS
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…
View Resource
New Biomarkers and Therapeutics Show Potential in Still's Disease
Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to…
View Resource
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved…
View Resource
Sleep Apnea Smart Watches (10.13.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past…
View Resource